An article in the September 25, 2020, issue of The ASCO Post, “Enthusiastic Response to Novel Therapies on the Horizon in Multiple Myeloma,” contained a couple of errors in its discussion of cereblon E3 ligase (CEL) modulators. The CEL modulator CC-92480 was misidentified (as CC-92380), and the reference cited for a phase I study of the compound was incorrect. The correct reference is:
Richardson PG, Vangsted AJ, Ramasamy K, et al: First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone in patients with relapsed/refractory multiple myeloma. ASCO20 Virtual Scientific Program. Abstract 8500.
We regret these errors, both of which have been corrected in the online version of the article, and we thank the reader who brought them to our attention.
